These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 11668667

  • 1. In healthy volunteers responses to challenge with cholecystokinin tetrapeptide differ between administration during REM and delta sleep.
    Kronenberg G, Schredl M, Fiedler K, Heuser I.
    Depress Anxiety; 2001; 14(2):141-4. PubMed ID: 11668667
    [Abstract] [Full Text] [Related]

  • 2. Megestrol attenuates the hormonal response to CCK-4-induced panic attacks.
    Raedler TJ, Jahn H, Goedeken B, Gescher DM, Kellner M, Wiedemann K.
    Depress Anxiety; 2006; 23(3):139-44. PubMed ID: 16470820
    [Abstract] [Full Text] [Related]

  • 3. A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder.
    Bradwejn J, Koszycki D, Annable L, Couëtoux du Tertre A, Reines S, Karkanias C.
    Biol Psychiatry; 1992 Nov 15; 32(10):903-12. PubMed ID: 1467375
    [Abstract] [Full Text] [Related]

  • 4. Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study.
    Zwanzger P, Eser D, Aicher S, Schüle C, Baghai TC, Padberg F, Ella R, Möller HJ, Rupprecht R.
    Neuropsychopharmacology; 2003 May 15; 28(5):979-84. PubMed ID: 12700707
    [Abstract] [Full Text] [Related]

  • 5. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings.
    Bradwejn J, Koszycki D, Shriqui C.
    Arch Gen Psychiatry; 1991 Jul 15; 48(7):603-10. PubMed ID: 2069490
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The effect of cholecystokinin tetrapeptide on respiratory resistance in healthy volunteers.
    Shlik J, Vasar V, Aluoja A, Kingisepp PH, Jagomägi K, Vasar E, Rägo L, Bradwejn J.
    Biol Psychiatry; 1997 Aug 01; 42(3):206-12. PubMed ID: 9232213
    [Abstract] [Full Text] [Related]

  • 9. Influence of personality on behavioral response to cholecystokinin-tetrapeptide in patients with panic disorder.
    Koszycki D, Zacharko RM, Bradwejn J.
    Psychiatry Res; 1996 May 17; 62(2):131-8. PubMed ID: 8771610
    [Abstract] [Full Text] [Related]

  • 10. Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder.
    Bradwejn J, Koszycki D, Meterissian G.
    Can J Psychiatry; 1990 Feb 17; 35(1):83-5. PubMed ID: 2180549
    [Abstract] [Full Text] [Related]

  • 11. Effects of low-dose cholecystokinin on respiratory function in healthy volunteers.
    Schruers K, Caycedo N, Overbeek T, Büchold H, Bourin M, Griez E.
    Eur Neuropsychopharmacol; 2000 Sep 17; 10(5):419-21. PubMed ID: 10974616
    [Abstract] [Full Text] [Related]

  • 12. Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder.
    Ströhle A, Holsboer F, Rupprecht R.
    Neuropsychopharmacology; 2000 Mar 17; 22(3):251-6. PubMed ID: 10693152
    [Abstract] [Full Text] [Related]

  • 13. Associations between personality traits and CCK-4-induced panic attacks in healthy volunteers.
    Tõru I, Aluoja A, Võhma U, Raag M, Vasar V, Maron E, Shlik J.
    Psychiatry Res; 2010 Jul 30; 178(2):342-7. PubMed ID: 20471107
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Anxiety sensitivity and response to cholecystokinin tetrapeptide in healthy volunteers.
    Koszycki D, Cox BJ, Bradwejn J.
    Am J Psychiatry; 1993 Dec 30; 150(12):1881-3. PubMed ID: 8238648
    [Abstract] [Full Text] [Related]

  • 16. Distinct panicogenic activity of sodium lactate and cholecystokinin tetrapeptide in patients with panic disorder.
    Plag J, Gaudlitz K, Zschucke E, Yassouridis A, Pyrkosch L, Wittmann A, Holsboer F, Ströhle A.
    Curr Pharm Des; 2012 Dec 30; 18(35):5619-26. PubMed ID: 22632477
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the effects of cholecystokinin-tetrapeptide and carbon dioxide in health volunteers.
    Koszycki D, Bradwejn J, Bourin M.
    Eur Neuropsychopharmacol; 1991 May 30; 1(2):137-41. PubMed ID: 1821703
    [Abstract] [Full Text] [Related]

  • 18. Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers.
    Zwanzger P, Baghai TC, Schuele C, Ströhle A, Padberg F, Kathmann N, Schwarz M, Möller HJ, Rupprecht R.
    Neuropsychopharmacology; 2001 Nov 30; 25(5):699-703. PubMed ID: 11682253
    [Abstract] [Full Text] [Related]

  • 19. Panic induction with cholecystokinin-tetrapeptide (CCK-4) Increases plasma concentrations of the neuroactive steroid 3alpha, 5alpha tetrahydrodeoxycorticosterone (3alpha, 5alpha-THDOC) in healthy volunteers.
    Eser D, di Michele F, Zwanzger P, Pasini A, Baghai TC, Schüle C, Rupprecht R, Romeo E.
    Neuropsychopharmacology; 2005 Jan 30; 30(1):192-5. PubMed ID: 15467707
    [Abstract] [Full Text] [Related]

  • 20. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers.
    Bradwejn J, Koszycki D, Paradis M, Reece P, Hinton J, Sedman A.
    Biol Psychiatry; 1995 Dec 01; 38(11):742-6. PubMed ID: 8580227
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.